small molecule

ENTOCORT EC

BUDESONIDE

Loss of exclusivityloss of exclusivity
CompanyPADAGIS US LLC

Drug detail

Brand nameENTOCORT EC
Active ingredientBUDESONIDE
Strength3MG
Dosage formCAPSULE, DELAYED RELEASE
RouteORAL
ModalitySmall molecule
FDA approvalOctober 2001
Marketing statusRX

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

ENTOCORT EC patent cliff — loss of exclusivity — | CliffBio